Induction of apoptosis in human multiple myeloma cell lines by ebselen via enhancing the endogenous reactive oxygen species production

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Zhang, Liang ^a   Zhou, Liwei ^a   Du, Jia ^a   Li, Mengxia ^a   Qian, Chengyuan ^a   Cheng, Yi ^a   Peng, Yang ^a   Xie, Jiayin ^a   Wang, Dong ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; CYTOCHROME C; EBSELEN; PROTEIN BAX; REACTIVE OXYGEN METABOLITE; ORGANOSELENIUM DERIVATIVE; PYRROLE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DAMAGE; CELL VIABILITY; CYTOSOL; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; MULTIPLE MYELOMA; BIOSYNTHESIS; CELL SURVIVAL; DRUG EFFECT; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; AZOLES; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; CELL SURVIVAL; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MULTIPLE MYELOMA; ORGANOSELENIUM COMPOUNDS; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 84896842295     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/696107     Document Type: Article

References (54)

1. Muller A., Cadenas E., Graf P., Sies H., A novel biologically active seleno-organic compound-I. Glutathione peroxidase-like activity in vitro and antioxidant capacity of PZ 51 (Ebselen). Biochemical Pharmacology 1984 33 20 3235 3239 2-s2.0-0021185122 10.1016/0006-2952(84)90083-2
2. Chew P., Yuen D. Y. C., Stefanovic N., Pete J., Coughlan M. T., Jandeleit-Dahm K. A., Thomas M. C., Rosenfeldt F., Cooper M. E., de Haan J. B., Antiatherosclerotic and renoprotective effects of ebselen in the diabetic apolipoprotein E/GPx1-double knockout mouse. Diabetes 2010 59 12 3198 3207 2-s2.0-78650042004 10.2337/db10-0195
3. Basarslan F., Yilmaz N., Davarci I., Effects of ebselen on radiocontrast media-induced hepatotoxicity in rats. Toxicology and Industrial Health 2013 29 8 746 752 10.1177/0748233712442730
4. Poyrazoglu Y., Yigit T., Harlak A., Mentes O., Gorgulu S., Uzar A. I., Kozak O., Effects of prevention of oxidative and nitro-oxidative stress on experimental rat colon anastomosis using acetylcysteine, ebselen and 1400w. Acta Chirurgica Belgica 2011 111 1 26 31 2-s2.0-79953700850
5. Tunc T., Uysal B., Atabek C., Kesik V., Caliskan B., Oztas E., Ersoz N., Oter S., Guven A., Erdosteine and ebselen as useful agents in intestinal ischemia/reperfusion injury. Journal of Surgical Research 2009 155 2 210 216 2-s2.0-67650932715 10.1016/j.jss.2008.06.017
6. Kizilgun M., Poyrazoglu Y., Oztas Y., Yaman H., Cakir E., Cayci T., Akgul O. E., Kurt Y. G., Yaren H., Kunak Z. I., MacIt E., Ozkan E., Taslipinar M. Y., Turker T., Ozcan A., Beneficial effects of N-acetylcysteine and ebselen on renal ischemia/reperfusion injury. Renal Failure 2011 33 5 512 517 2-s2.0-79956275143 10.3109/0886022X.2011.574767
7. Yin Z., Lee E., Ni M., Jiang H., Milatovic D., Rongzhu L., Farina M., Rocha J. B. T., Aschner M., Methylmercury-induced alterations in astrocyte functions are attenuated by ebselen. NeuroToxicology 2011 32 3 291 299 2-s2.0-79952204260 10.1016/j.neuro.2011.01.004
8. Koizumi H., Fujisawa H., Suehiro E., Shirao S., Suzuki M., Neuroprotective effects of ebselen following forebrain ischemia: involvement of glutamate and nitric oxide. Neurologia Medico-Chirurgica 2011 51 5 337 343 2-s2.0-79957969635 10.2176/nmc.51.337
9. Seo J. Y., Lee C. H., Cho J. H., Choi J. H., Yoo K.-Y., Kim D. W., Park O. K., Li H., Choi S. Y., Hwang I. K., Won M.-H., Neuroprotection of ebselen against ischemia/reperfusion injury involves GABA shunt enzymes. Journal of the Neurological Sciences 2009 285 1-2 88 94 2-s2.0-69549135250 10.1016/j.jns.2009. 05.029
10. Lu J., Berndt C., Holmgren A., Metabolism of selenium compounds catalyzed by the mammalian selenoprotein thioredoxin reductase. Biochimica et Biophysica Acta 2009 1790 11 1513 1519 2-s2.0-72649091301 10.1016/j.bbagen.2009.04.013
11. Zhao R., Holmgren A., A novel antioxidant mechanism of ebselen involving ebselen diselenide, a substrate of mammalian thioredoxin and thioredoxin reductase. Journal of Biological Chemistry 2002 277 42 39456 39462 2-s2.0-0037131424 10.1074/jbc.M206452200
12. Muller A., Gabriel H., Sies H., Terlinden R., Fischer H., Romer A., A novel biologically active selenoorganic compound-VII. Biotransformation of ebselen in perfused rat liver. Biochemical Pharmacology 1988 37 6 1103 1109 2-s2.0-0023832899
13. Shi H., Liu S., Miyake M., Liu K. J., Ebselen induced C6 glioma cell death in oxygen and glucose deprivation. Chemical Research in Toxicology 2006 19 5 655 660 2-s2.0-33744478633 10.1021/tx0502544
14. Engman L., Cotgreave I., Angulo M., Taylor C. W., Paine-Murrieta G. D., Powis G., Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents. Anticancer Research 1997 17 6 4599 4605 2-s2.0-0031425497
15. Yang C.-F., Shen H.-M., Ong C.-N., Ebselen induces apoptosis in HepG2 cells through rapid depletion of intracellular thiols. Archives of Biochemistry and Biophysics 2000 374 2 142 152 2-s2.0-0034652202 10.1006/abbi.1999.1574
16. Guérin P. J., Gauthier E. R., Induction of cellular necrosis by the glutathione peroxidase mimetic ebselen. Journal of Cellular Biochemistry 2003 89 1 203 211 2-s2.0-0344490255 10.1002/jcb.10500
17. Brunelle J. K., Letai A., Control of mitochondrial apoptosis by the Bcl-2 family. Journal of Cell Science 2009 122 part 4 437 441 2-s2.0-64849113485 10.1242/jcs.031682
18. Allan D. J., Howell A., Roberts S. A., Williams G. T., Watson R. J., Coyne J. D., Clarke R. B., Laidlaw I. J., Potten C. S., Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast. Journal of Pathology 1992 167 1 25 32 2-s2.0-0026560861 10.1002/path.1711670106
19. Simon H.-U., Haj-Yehia A., Levi-Schaffer F., Role of reactive oxygen species (ROS) in apoptosis induction. Apoptosis 2000 5 5 415 418 2-s2.0-0034468736 10.1023/A:1009616228304
20. Behrend L., Henderson G., Zwacka R. M., Reactive oxygen species in oncogenic transformation. Biochemical Society Transactions 2003 31 part 6 1441 1444 2-s2.0-0348049803
21. Toyokuni S., Persistent oxidative stress in cancer. FEBS Letters 1995 358 1 1 3 2-s2.0-0028900690 10.1016/0014-5793(94)01368-B
22. Gomez-Lazaro M., Galindo M. F., Melero-Fernandez De Mera R. M., Fernandez-Gómez F. J., Concannon C. G., Segura M. F., Comella J. X., Prehn J. H. M., Jordan J., Reactive oxygen species and p38 mitogen-activated protein kinase activate bax to induce mitochondrial cytochrome c release and apoptosis in response to malonate. Molecular Pharmacology 2007 71 3 736 743 2-s2.0-33847109840 10.1124/mol.106.030718
23. Mahindra A., Hideshima T., Anderson K. C., Multiple myeloma: biology of the disease. Blood Reviews 2010 24 supplement 1 S5 S11 2-s2.0-78649713701 10.1016/S0268-960X(10)70003-5
24. Austin C. P., Brady L. S., Insel T. R., Collins F. S., NIH molecular libraries initiative. Science 2004 306 5699 1138 1139 2-s2.0-8444225024 10.1126/science.1105511
25. Meotti F. C., Borges V. C., Zeni G., Rocha J. B. T., Nogueira C. W., Potential renal and hepatic toxicity of diphenyl diselenide, diphenyl ditelluride and ebselen for rats and mice. Toxicology Letters 2003 143 1 9 16 2-s2.0-0037420886 10.1016/S0378-4274(03)00090-0
26. Yamaguchi T., Sano K., Takakura K., Saito I., Shinohara Y., Asano T., Yasuhara H., Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Stroke 1998 29 1 12 17 2-s2.0-0031963836
27. Ozgur T., Tutanc M., Zararsiz I., The protective effect of ebselen on radiocontrast-induced nephrotoxicity. Renal Failure 2012 34 8 991 997 10.3109/0886022X.2012.706880
28. Sharma V., Tewari R., Sk U. H., Joseph C., Sen E., Ebselen sensitizes glioblastoma cells to Tumor Necrosis Factor (TNF α)-induced apoptosis through two distinct pathways involving NF- B downregulation and Fas-mediated formation of death inducing signaling complex. International Journal of Cancer 2008 123 9 2204 2212 2-s2.0-51649089169 10.1002/ijc.23771
29. Maraldi T., Prata C., Fiorentini D., Zambonin L., Landi L., Hakim G., Induction of apoptosis in a human leukemic cell line via reactive oxygen species modulation by antioxidants. Free Radical Biology and Medicine 2009 46 2 244 252 2-s2.0-58049114757 10.1016/j.freeradbiomed.2008.10.027
30. Puntel R. L., Roos D. H., Seeger R. L., Mitochondrial electron transfer chain complexes inhibition by different organochalcogens. Toxicology in Vitro 2013 27 1 59 70 10.1016/j.tiv.2012.10.011
31. Puntel R. L., Roos D. H., Seeger R. L., Organochalcogens inhibit mitochondrial complexes I and II in rat brain: possible implications for neurotoxicity. Neurotoxicity Research 2013 24 2 109 118 10.1007/s12640-012-9365- 0
32. Puntel R. L., Roos D. H., Folmer V., Nogueira C. W., Galina A., Aschner M., Rocha J. B. T., Mitochondrial dysfunction induced by different organochalchogens is mediated by thiol oxidation and is not dependent of the classical mitochondrial permeability transition pore opening. Toxicological Sciences 2010 117 1 133 143 2-s2.0-77955861745 10.1093/toxsci/kfq185
33. Zhao R., Masayasu H., Holmgren A., Ebselen: a substrate for human thioredoxin reductase strongly stimulating its hydroperoxide reductase activity and a superfast thioredoxin oxidant. Proceedings of the National Academy of Sciences of the United States of America 2002 99 13 8579 8584 2-s2.0-0037172997 10.1073/pnas.122061399
34. Morin D., Zini R., Ligeret H., Neckameyer W., Labidalle S., Tillement J.-P., Dual effect of ebselen on mitochondrial permeability transition. Biochemical Pharmacology 2003 65 10 1643 1651 2-s2.0-0038730947 10.1016/S0006-2952(03)00114-X
35. Billen L. P., Kokoski C. L., Lovell J. F., Leber B., Andrews D. W., Bcl-XL inhibits membrane permeabilization by competing with Bax. PLoS Biology 2008 6 6, article e147 2-s2.0-53049102176 10.1371/journal.pbio.0060147
36. Wang X., The expanding role of mitochondria in apoptosis. Genes and Development 2001 15 22 2922 2933 2-s2.0-0035890085
37. Antony S., Bayse C. A., Modeling the mechanism of the glutathione peroxidase mimic ebselen. Inorganic Chemistry 2011 50 23 12075 12084 2-s2.0-81255130972 10.1021/ic201603v
38. Sarma B. K., Mugesh G., Antioxidant activity of the anti-inflammatory compound ebselen: a reversible cyclization pathway via selenenic and seleninic acid intermediates. Chemistry 2008 14 34 10603 10614 2-s2.0-56749091434 10.1002/chem.200801258
39. Nogueira C. W., Rocha J. B. T., Toxicology and pharmacology of selenium: emphasis on synthetic organoselenium compounds. Archives of Toxicology 2011 85 11 1313 1359 2-s2.0-80755153273 10.1007/s00204-011-0720-3
40. Deneke S. M., Thiol-based antioxidants. Current Topics in Cellular Regulation 2001 36 151 180 2-s2.0-0033655899 10.1016/S0070-2137(01)80007-8
41. Puntel R. L., Roos D. H., Seeger R. L., Rocha J. B.T., Mitochondrial electron transfer chain complexes inhibition by different organochalcogens. Toxicology in Vitro 2013 27 1 59 70 10.1016/j.tiv.2012.10.011
42. Fruehauf J. P., Meyskens F. L. Jr., Reactive oxygen species: a breath of life or death? Clinical Cancer Research 2007 13 3 789 794 2-s2.0-33847349283 10.1158/1078-0432.CCR-06-2082
43. Schumacker P. T., Reactive oxygen species in cancer cells: live by the sword, die by the sword. Cancer Cell 2006 10 3 175 176 2-s2.0-33748165596 10.1016/j.ccr.2006.08.015
44. Kim S.-J., Park C., Han A. L., Youn M.-J., Lee J.-H., Kim Y., Kim E.-S., Kim H.-J., Kim J.-K., Lee H.-K., Chung S.-Y., So H., Park R., Ebselen attenuates cisplatin-induced ROS generation through Nrf2 activation in auditory cells. Hearing Research 2009 251 1-2 70 82 2-s2.0-64249150219 10.1016/j.heares.2009.03. 003
45. Lynch E. D., Gu R., Pierce C., Kil J., Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hearing Research 2005 201 1-2 81 89 2-s2.0-13844266756 10.1016/j.heares.2004.08.002
46. Hardej D., Trombetta L. D., The effects of ebselen on cisplatin and diethyldithiocarbamate (DDC) cytotoxicity in rat hippocampal astrocytes. Toxicology Letters 2002 131 3 215 226 2-s2.0-0037188445 10.1016/S0378-4274(02) 00056-5
47. Yoshida M., Iizuka K., Terada A., Hara M., Nishijima H., Shimada A., Nakada K., Satoh Y., Akama Y., Prevention of nephrotoxicity of cisplatin by repeated oral administration of ebselen in rats. Tohoku Journal of Experimental Medicine 2000 191 4 209 220 2-s2.0-0033637974
48. Husain K., Morris C., Whitworth C., Trammell G. L., Rybak L. P., Somani S. M., Protection by ebselen against cisplatin-induced nephrotoxicity: antioxidant system. Molecular and Cellular Biochemistry 1998 178 1-2 127 133 2-s2.0-0031912696 10.1023/A:1006889427520
49. Baldew G. S., Boymans A. P., Mol J. G. J., Vermeulen N. P. E., The influence of ebselen on the toxicity of cisplatin in LLC-PK1 cells. Biochemical Pharmacology 1992 44 2 382 387 2-s2.0-0026716075 10.1016/0006-2952(92)90024-D
50. Baldew G. S., McVie J. G., van der Valk M. A., Los G., de Goeij J. J. M., Vermeulen N. P. E., Selective reduction of cis-diamminedichloroplatinum(II) nephrotoxicity by ebselen. Cancer Research 1990 50 21 7031 7036 2-s2.0-0025049004
51. Saad S. Y., Najjar T. A., Arafah M. M., Cardioprotective effects of subcutaneous ebselen against daunorubicin-induced cardiomyopathy in rats. Basic and Clinical Pharmacology and Toxicology 2006 99 6 412 417 2-s2.0-33751372282 10.1111/j.1742-7843.2006.pto-523.x
52. Tripathi D. N., Jena G. B., Ebselen attenuates cyclophosphamide-induced oxidative stress and DNA damage in mice. Free Radical Research 2008 42 11-12 966 977 2-s2.0-57649238084 10.1080/10715760802566558
53. Kotamraju S., Konorev E. A., Joseph J., Kalyanaraman B., Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen. Role of reactive oxygen and nitrogen species. Journal of Biological Chemistry 2000 275 43 33585 33592 2-s2.0-0034721770 10.1074/jbc.M003890200
54. Lynch E. D., Gu R., Pierce C., Kil J., Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing anti-tumor activity. Anti-Cancer Drugs 2005 16 5 569 579 2-s2.0-18844383751 10.1097/00001813-200506000-00013